Warp Speed keeps on giving
The latest Covid-19 vaccine award sees Glaxo and Sanofi score a $2.1bn windfall from the US government.
Go or no go? Valuable drugs set for FDA decisions
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
